Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients.
BACKGROUND
Marked variations in cell size (polymegethism) and shape (pleomorphism) are characteristic of the corneal endothelium in diabetic patients and animals.


METHODS
Wide field specular microscopy was used to evaluate the clinical efficacy of treating the diabetic corneal endothelium with topical instillation of 0.5% aldose reductase inhibitor, CT-112.


RESULTS
Morphological variations (polymegethism and pleomorphism) of the endothelium in eight eyes from eight patients receiving CT-112 resolved within 3 months after initiation of treatment. In contrast, no change in endothelial morphology was noted in five eyes from five patients who received placebo.


CONCLUSIONS
These observations suggest that aldose reductase may be involved in the aetiology of corneal endothelial variations in diabetic patients.
Ohguro
N
N
Department of Ophthalmology, Osaka University Medical School, Japan.
Matsuda
M
M
Ohashi
Y
Y
Fukuda
M
M
D000287:Administration, Topical; D000368:Aged; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D048429:Cell Size; D003316:Corneal Diseases / Q000188:drug therapy* / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004728:Endothelium, Corneal / Q000473:pathology*; D006801:Humans; D008875:Middle Aged; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D045162:Thiazolidinediones
D013844:Thiazoles; D045162:Thiazolidinediones; C051003:risarestat; D000449:Aldehyde Reductase